GlycoMantra has been awarded a two-year SBIR Phase 2 grant ($3.7 M) from the NIDDK…
GlycoMantra received a SBIR Phase 1 grant from the NIDDK (NIH)
June 03, 2020
GlycoMantra was awarded a SBIR Phase 1 grant to investigate insulin resistance in type 2 diabetes.
